OIRA Conclusion of EO 12866 Regulatory Review
RIN: 0910-ZB95 View EO 12866 Meetings | Received Date: 03/07/2024 |
Title: Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency; Draft Guidance for Industry and Food and Drug Administration Staff; Availability | |
Agency/Subagency: HHS / FDA | Stage: Notice |
Concluded Action: Consistent with Change | Concluded Date: 04/22/2024 |
Section 3(f)(1) Significant *: No | |
Legal Deadline: None | Economically Significant **: No |
Publication Date: | Unfunded Mandates: No |
Major: No | Related To Homeland Security: No |
Regulatory Flexibility Analysis Required: No | Small Entities Affected: |
Federalism Implications: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
International Impacts: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |
Pandemic Response: No | |
|